Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704781 | 0.98 | LMNA (0.44) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL697772 | 0.94 | LMNA (0.41) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL697011 | 0.90 | LMNA (0.35) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL4490756 | 0.82 | EPHX1 (0.40) | LMNAMEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL6886924 | 0.82 | LMNA (0.45) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL1669840 | 0.82 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL23129641 | 0.80 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL1672623 | 0.80 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL4630436 | 0.79 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL698391 | 0.79 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130143886-A1 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130012553-A1 | METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2013-01-10 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2097079-B1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER FLEMING LTD (GB) | 2012-06-27 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-5002972-A | Compound and composition of substituted hexenoic acid derivatives useful for treating thromboxane A2 mediated diseases | SHIONOGI & CO., LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| EP-0415566-A1 | Heterocyclic compounds, processes for producing them and pharmaceutical compositions comprising them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4960880-A | STEREOSPECIFIC SYNTHESIS OF B-LACTAM INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| EP-0384747-A1 | Pharmaceutical or veterinary preparations of substituted hexenoic acid derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0348203-A1 | Phenolic thioethers, their production and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | XDH, REN, CYP11B2 | LMNA 377/4885SLC1A3 669/4885SLC1A2 610/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | LMNA 4436/4885SLC1A3 3327/4885SLC1A2 2104/4885 |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | LMNA 4293/4885SLC1A3 4419/4885SLC1A2 4407/4885 |
| US-20130143886-A1 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS | XDH, GLS, REN | LMNA 1663/4885SLC1A3 1956/4885SLC1A2 1921/4885 |
| US-20130012553-A1 | METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS | XDH, AOX1, NQO1 | LMNA 2047/4885SLC1A3 2368/4885SLC1A2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.